<DOC>
	<DOCNO>NCT00684008</DOCNO>
	<brief_summary>This phase I inter-patient dose escalation open label study assess multiple dos CYT107 patient least 15 year age , recipient HLA match ex vivo T cell deplete bone marrow peripheral blood stem transplant . The dose escalation design aim establish absence significant toxicity define biologically active dose patient population . At dose level , eligible patient receive 3 dos CYT107 inject subcutaneously ( skin arm , leg , stomach ) week 3 week . Groups three patient enter dose level CYT107 . Three dose level plan : 10 mcg/kg/week , 20 mcg/kg/week 30 mcg/kg/week . Three patient must complete day 42 study dose level without dose limit toxicity ( DLT ) escalation next dose level .</brief_summary>
	<brief_title>Safety Study IL-7 Recipients Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant</brief_title>
	<detailed_description>Rationale : Delayed deficient reconstitution T cell function major obstacle success hematopoietic stem cell transplant ( HSCT ) . CYT-107 may potential clinical use allogeneic HSCT enhance lymphoid reconstitution could number beneficial effect include decreased morbidity mortality post-transplant infection . Our preliminary data previous generation IL-7 , CYT 99 007 , raise possibility IL-7 could , case , anti-GVHD effect keep anti-tumor effect allograft intact . Primary Objective : - To determine safety recommend dose CYT107 ( r-hIL-7 ) recipients HLA-matched related unrelated ex vivo T-cell-depleted bone marrow ( BM ) peripheral blood stem cell ( PBSC ) transplant initial engraftment hematopoietic reconstitution . - If toxicity encounter , establish maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) . Secondary Objectives : - To define pharmacokinetics escalate dos CYT107 recipient allogeneic transplant . To achieve preliminary characterization : - Of effect CYT107 treatment engraftment GVHD . - Of effect CYT107 recovery T , NK B cell population function vitro . - Of tolerable biologically active range dos CYT107 recipient allogeneic transplant . - Whether degree administration CYT107 might influence risk develop EBV-lymphoproliferative disorder . - Of effect CYT107 treatment leukemia relapse .</detailed_description>
	<criteria>Able read consent form give inform consent . At least 15 year old . Histologically confirm nonlymphoid hematological malignancy . Recipient T cell deplete bone marrow ( BM ) peripheral blood stem cell ( PBSC ) transplant 6/6 HLA ( A , B , DR intermediate resolution ) identical relate unrelated donor myeloablative conditioning . Received TCD HCT contain &lt; 1x105 CD3+ T cells/kg recipient . Patient include least one follow category : AML 2nd great complete remission . Highrisk AML ( highrisk cytogenetics , undifferentiated leukemia , secondary AML , antecedent MDS ) 1st remission . CML 2nd great chronic phase , 2nd great accelerate phase . MDS intermediate high risk IPSS criterion . History opportunistic infection ( CMV viremia require antiviral therapy , PCP pneumonia , mycobacterial infection , herpes zoster , viral respiratory infection ( influenza , RSV , parainfluenza ) , etc . CD4+ T cell count &lt; 100 6 month posttransplant . At high risk opportunistic infection ( e.g. , history treat invasive fungal infection prior transplantation , positive CMV serology patient , positive toxoplasmosis serology donor patient , etc. ) . 60 210 day post transplant . In remission time initiation CYT107 . Documented engraftment sustain neutrophil count least 1000/mcl untransfused platelet count &gt; 20 000/mcl 3 consecutive lab value ( last one test &lt; 10 day initiation treatment ) 3 different day prior treatment . Patients engraft require GCSF myelosuppressive antibiotic antiviral medication eligible require GCSF twice weekly ANC remain &gt; 1000/mcl . KPS &gt; 60 % . Adequate organ function : Cardiac : No evidence change cardiac function history , exam and/or EKG postHCT . Pulmonary : Absence dyspnea hypoxia ( &lt; 90 % saturation pulse oxymetry room air ) . Hepatic : Bilirubin &lt; = 1.5 X ULN , AST ( SGOT ) /or ALT ( SGPT ) &lt; = 2.5 X ULN . PT/PTT &lt; 1.5 X ULN . Renal : Calculated Creatinine clearance &gt; 60 mL/min/1.73 m2 . [ Note : transplant patient ejection fraction &gt; 40 % pretransplant echocardiogram DLCO &gt; 50 % predict ( correct hemoglobin ) ] No evidence history acute GVHD chronic GVHD . No recurrent leukemia post HCT . No active uncontrolled viral , bacterial fungal infection . No documented HIV1 2 , HBV HCV infection time transplant ( positive hepatitis B serology indicative previous immunization exclusion criterion ) . Not receive systemic corticosteroid , antimitotic agent immunosuppressive treatment . Not receive Growth Hormone gonadotropin agonists/ antagonist . Not receive cytokine support GCSF postHCT . Not receive concurrent treatment another investigational drug and/or biological agent . Not receive anticoagulant therapy . No uncontrolled hypertension . No history lymphoid malignancy ( e.g . Hodgkin disease , non Hodgkin lymphoma , Acute Lymphoblastic Leukemia Chronic Lymphocytic Leukemia ) acute biphenotypic leukemia . No peripheral lymphadenopathy ( lymph node &gt; 1 cm ) . No history EBV associate lymphoproliferation . No EBV viremia equal great 500 copy EBV DNA/mL blood quantitative PCR . No history autoimmune disease HCT donor history autoimmune disease . Fertile patient must use effective birth control . Not pregnant nursing . Negative pregnancy test within 2 week study treatment . QTc prolongation ( QTc &gt; 470 m ) prior history significant arrhythmia ECG abnormality . No active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Any past current psychiatric illness , opinion investigator , would interfere adherence study requirement ability willingness give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune base therapy</keyword>
	<keyword>graft v host disease</keyword>
	<keyword>immune reconstitution</keyword>
	<keyword>infection</keyword>
	<keyword>lymphopenia</keyword>
	<keyword>hematopoetic stem cell transplantation</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>peripheral blood stem cell transplant</keyword>
	<keyword>immunosuppression</keyword>
</DOC>